Dr Reddy’s Laboratories reports Q3 net profit of Rs 27.9 cr

By: |
January 29, 2021 12:48 PM

The company had posted a net loss of Rs 538.4 crore during the same period of the previous fiscal.

API supplies for Vascepa are an issueAPI supplies for Vascepa are an issue

Dr Reddy”s Laboratories on Friday posted a consolidated net profit of Rs 27.9 crore for the third quarter ended December 31, 2020. The company had posted a net loss of Rs 538.4 crore during the same period of the previous fiscal.

Its total revenue from operations stood at Rs 4,941.9 crore for the quarter under review, up 12.38 per cent. During the third quarter ended December 31, 2019, the total revenue from operations was at Rs 4,397.1 crore, Dr Reddy”s Laboratories said in a regulatory filing.

“We continued with our growth momentum while maintaining EBITDA (earnings before interest, taxes, depreciation and amortisation) margins,” Dr Reddy”s Laboratories Co-chairman and MD G V Prasad said.

Prasad said the profits were impacted due to trigger-based impairment charge taken on a few acquired products. “We are progressing well on phase 3 clinical trials for Sputnik V vaccine in India. We continue to focus on enhancing our product offerings to our patients to serve them better,” he added.

Shares of Dr Reddy”s Labs were trading 3.07 per cent lower at Rs 4,726.60 apiece on BSE

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Cairn identifies $70 bn Indian assets for seizing to recover amount due from govt
2Sales of AC, other cooling products again hit by pandemic in peak season; cos now pin hopes on extended summer
3StanPlus plans to add 3,000 ambulances with ventilators across India in 3 years